Roche extends cash tender offer to acquire all shares of Illumina

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ILMN), at a price of $44.50 per share, to 6:00 p.m., New York City time, on March 23, 2012. The tender offer was previously scheduled to expire at 12:00 midnight, New York City time, at the end of the day on February 24, 2012.

All other terms and conditions of the offer remain unchanged. As of 12:00 midnight, New York City time, at the end of the day on February 24, 2012, approximately 102,165 shares, including 44,152 shares guaranteed to be delivered within the next three NASDAQ trading days, had been tendered and not withdrawn pursuant to the offer.

Source:

Roche

Posted in: Business / Finance

Tags: , , , , , ,

Comments (0)

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2019, June 19). Roche extends cash tender offer to acquire all shares of Illumina. News-Medical. Retrieved on December 03, 2024 from https://www.news-medical.net/news/20120227/Roche-extends-cash-tender-offer-to-acquire-all-shares-of-Illumina.aspx.

  • MLA

    Illumina, Inc.. "Roche extends cash tender offer to acquire all shares of Illumina". News-Medical. 03 December 2024. <https://www.news-medical.net/news/20120227/Roche-extends-cash-tender-offer-to-acquire-all-shares-of-Illumina.aspx>.

  • Chicago

    Illumina, Inc.. "Roche extends cash tender offer to acquire all shares of Illumina". News-Medical. https://www.news-medical.net/news/20120227/Roche-extends-cash-tender-offer-to-acquire-all-shares-of-Illumina.aspx. (accessed December 03, 2024).

  • Harvard

    Illumina, Inc.. 2019. Roche extends cash tender offer to acquire all shares of Illumina. News-Medical, viewed 03 December 2024, https://www.news-medical.net/news/20120227/Roche-extends-cash-tender-offer-to-acquire-all-shares-of-Illumina.aspx.

Suggested Reading

Illumina's board appoints Jacob Thaysen, Ph.D. as its new Chief Executive Officer
Illumina launches its first product enabling long- and short-read sequencing on one instrument
NovaSeq, the new sequencer by Illumina, said to transform the field of genomics
Illumina debuts new software to optimize data analysis for noninvasive prenatal testing
Illumina donates more than 95,000 human genetic variants to ClinVar database
Pioneering Genomic Progress: An Interview with Rami Mehio, Illumina's Software and Informatics Expert
Illumina and IBM join forces to grow accessibility to genome data interpretation
Equipment for single-cell genomics launched by Illumina and Bio-Rad

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Trending Stories

More Content from Illumina, Inc.

See all content from Illumina, Inc.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
MLL, IBM and Illumina collaborate to build new cognitive technology prototype for improving leukemia treatment